MedTrace Logo

Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors

NCT00003697 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor.

PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with solid tumors that have not responded to previous therapy.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

vadimezan

Sponsors & Collaborators

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Gordon J.S. Rustin, MD · Mount Vernon Cancer Centre at Mount Vernon Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-10-31
Completion
1998-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003697 on ClinicalTrials.gov